<DOC>
	<DOCNO>NCT01677598</DOCNO>
	<brief_summary>The purpose study determine patient use ustekinumab ( label-recommended other/missed dose interval ) Asia-Pacific country .</brief_summary>
	<brief_title>A Study Evaluate Ustekinumab Patients With Plaque Psoriasis Asia-Pacific Countries</brief_title>
	<detailed_description>This open-label ( people know identity medication ) , multicenter , Phase 4 , observational study ( study medication administer study ) design assess patient use ustekinumab ( label-recommended other/missed dose interval ) Asia-Pacific country . The study consist 4 study visit take place duration 1 year . At first visit ( ie , Week 0 ) , eligibility study determine ( screen baseline visit ) . At subsequent visit ( Weeks 16 , 28 , 52 ) , exposure ustekinumab record , questionnaires efficacy complete , information adverse event concomitant medication collect . As many patient report outcome questionnaire possible administer , depend availability validate translation . Safety assess monitor adverse event , vital sign physical examination .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Have diagnosis plaque psoriasis , accord dermatologist ' clinical judgment Agree initiate treatment ustekinumab day enrollment study Have receive antiIL12/23 therapy within 6 month prior enrollment study Has difficulty understand question pose questionnaire Are currently participate investigational drug clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>CNTO 1275</keyword>
	<keyword>Asia-Pacific</keyword>
</DOC>